Which has stronger valuation & earnings, BLTE or MLYS?

Belite Bio is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.73 N/A Mineralys Therapeutics N/A N/A -$154.65M -$4.24 N/A

Is BLTE or MLYS more profitable?

Belite Bio's return on equity of -11.84% beat Mineralys Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -11.84% -11.62% Mineralys Therapeutics N/A -57.97% -54.15%

Does the media favor BLTE or MLYS?

In the previous week, Mineralys Therapeutics had 6 more articles in the media than Belite Bio. MarketBeat recorded 11 mentions for Mineralys Therapeutics and 5 mentions for Belite Bio. Mineralys Therapeutics' average media sentiment score of 0.45 beat Belite Bio's score of 0.20 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MLYS or LNTH?

In the previous week, Mineralys Therapeutics had 2 more articles in the media than Lantheus. MarketBeat recorded 11 mentions for Mineralys Therapeutics and 9 mentions for Lantheus. Mineralys Therapeutics' average media sentiment score of 0.45 beat Lantheus' score of 0.27 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MLYS or AMRX?

In the previous week, Mineralys Therapeutics had 9 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 11 mentions for Mineralys Therapeutics and 2 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.59 beat Mineralys Therapeutics' score of 0.45 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LQDA or MLYS?

In the previous week, Liquidia had 29 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 40 mentions for Liquidia and 11 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.45 beat Liquidia's score of 0.13 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 7 Very Positive mention(s) 8 Positive mention(s) 13 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Neutral Mineralys Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, DFTX or MLYS?

Definium Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A Mineralys Therapeutics N/A N/A -$154.65M -$4.24 N/A

Is DFTX or MLYS more profitable?

Mineralys Therapeutics' return on equity of -57.97% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -84.01% -63.66% Mineralys Therapeutics N/A -57.97% -54.15%

Does the media favor DFTX or MLYS?

In the previous week, Definium Therapeutics had 7 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 18 mentions for Definium Therapeutics and 11 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.45 beat Definium Therapeutics' score of 0.31 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Mineralys Therapeutics (MLYS) Competitors

$23.30 -0.33 (-1.40%)

Closing price 04:00 PM Eastern

Extended Trading

$23.30 +0.00 (+0.02%)

As of 07:30 PM Eastern

Compare

MLYS vs. BLTE, LNTH, AMRX, LQDA, and DFTX

Should you buy Mineralys Therapeutics stock or one of its competitors? Mineralys Therapeutics's main competitors and comparable companies include Belite Bio (BLTE), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), Liquidia (LQDA), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Mineralys Therapeutics compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Belite Bio's return on equity of -11.84% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Mineralys Therapeutics	N/A	-57.97%	-54.15%

Belite Bio has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Belite Bio currently has a consensus target price of $218.73, suggesting a potential upside of 37.08%. Mineralys Therapeutics has a consensus target price of $48.80, suggesting a potential upside of 106.52%. Given Mineralys Therapeutics' higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Mineralys Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Belite Bio is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A

In the previous week, Mineralys Therapeutics had 6 more articles in the media than Belite Bio. MarketBeat recorded 11 mentions for Mineralys Therapeutics and 5 mentions for Belite Bio. Mineralys Therapeutics' average media sentiment score of 0.45 beat Belite Bio's score of 0.20 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mineralys Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Mineralys Therapeutics beats Belite Bio on 7 of the 13 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Lantheus?

Mineralys Therapeutics (NASDAQ:MLYS) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Mineralys Therapeutics currently has a consensus target price of $48.80, suggesting a potential upside of 106.52%. Lantheus has a consensus target price of $108.11, suggesting a potential upside of 8.15%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Mineralys Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

Lantheus has a net margin of 17.69% compared to Mineralys Therapeutics' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-57.97%	-54.15%
Lantheus	17.69%	28.10%	14.35%

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Mineralys Therapeutics had 2 more articles in the media than Lantheus. MarketBeat recorded 11 mentions for Mineralys Therapeutics and 9 mentions for Lantheus. Mineralys Therapeutics' average media sentiment score of 0.45 beat Lantheus' score of 0.27 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.14

Summary

Lantheus beats Mineralys Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Amneal Pharmaceuticals?

Mineralys Therapeutics (NASDAQ:MLYS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Mineralys Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

Mineralys Therapeutics presently has a consensus target price of $48.80, suggesting a potential upside of 106.52%. Amneal Pharmaceuticals has a consensus target price of $21.00, suggesting a potential upside of 3.45%. Given Mineralys Therapeutics' higher probable upside, research analysts clearly believe Mineralys Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Amneal Pharmaceuticals has a net margin of 5.05% compared to Mineralys Therapeutics' net margin of 0.00%. Mineralys Therapeutics' return on equity of -57.97% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-57.97%	-54.15%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Amneal Pharmaceuticals has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A
Amneal Pharmaceuticals	$3.02B	2.15	$72.06M	$0.49	41.43

In the previous week, Mineralys Therapeutics had 9 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 11 mentions for Mineralys Therapeutics and 2 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.59 beat Mineralys Therapeutics' score of 0.45 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Amneal Pharmaceuticals beats Mineralys Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Liquidia has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	16.19	-$68.92M	$1.37	20.91
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A

Liquidia has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Liquidia currently has a consensus target price of $83.69, suggesting a potential upside of 192.22%. Mineralys Therapeutics has a consensus target price of $48.80, suggesting a potential upside of 106.52%. Given Liquidia's higher possible upside, research analysts clearly believe Liquidia is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25
Mineralys Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Liquidia has a net margin of 30.74% compared to Mineralys Therapeutics' net margin of 0.00%. Liquidia's return on equity of 149.65% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Mineralys Therapeutics	N/A	-57.97%	-54.15%

In the previous week, Liquidia had 29 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 40 mentions for Liquidia and 11 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.45 beat Liquidia's score of 0.13 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	7 Very Positive mention(s)	8 Positive mention(s)	13 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Neutral
Mineralys Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Liquidia beats Mineralys Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Definium Therapeutics has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Definium Therapeutics presently has a consensus price target of $64.88, suggesting a potential upside of 73.46%. Mineralys Therapeutics has a consensus price target of $48.80, suggesting a potential upside of 106.52%. Given Mineralys Therapeutics' higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00
Mineralys Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Definium Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A

Mineralys Therapeutics' return on equity of -57.97% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Mineralys Therapeutics	N/A	-57.97%	-54.15%

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Definium Therapeutics had 7 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 18 mentions for Definium Therapeutics and 11 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.45 beat Definium Therapeutics' score of 0.31 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mineralys Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Mineralys Therapeutics beats Definium Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Mineralys Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLYS vs. The Competition

Export

Metric	Mineralys Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.09B	$12.22B	$7.14B	$13.26B
Dividend Yield	N/A	2.65%	2.53%	17.34%
P/E Ratio	-5.50	799.72	274.32	26.20
Price / Sales	N/A	756.29	618.16	93.09
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	2.85	10.68	11.23	6.40
Net Income	-$154.65M	$2.83B	$3.49B	$381.07M
7 Day Performance	-9.09%	-2.20%	-1.68%	-0.65%
1 Month Performance	-17.41%	-6.55%	-5.97%	-4.51%
1 Year Performance	-38.78%	-4.52%	8.11%	1.82%

Mineralys Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLYS Mineralys Therapeutics	2.9359 of 5 stars	$23.30 -1.4%	$48.80 +109.4%	-37.9%	$2.09B	N/A	N/A	76	Insider Trade
BLTE Belite Bio	3.3515 of 5 stars	$167.27 +0.8%	$218.73 +30.8%	+111.1%	$6.76B	N/A	N/A	41	Analyst Forecast
LNTH Lantheus	3.0407 of 5 stars	$99.60 -0.1%	$108.11 +8.6%	+85.7%	$6.50B	$1.54B	24.06	1,193
AMRX Amneal Pharmaceuticals	3.3374 of 5 stars	$20.20 -1.5%	$21.00 +4.0%	+95.4%	$6.45B	$3.02B	41.24	8,500
LQDA Liquidia	4.0968 of 5 stars	$70.52 -4.3%	$98.08 +39.1%	+27.7%	$6.30B	$158.32M	51.41	216	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLYS) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. BLTE, LNTH, AMRX, LQDA, and DFTX

How does Mineralys Therapeutics compare to Belite Bio?

Summary

How does Mineralys Therapeutics compare to Lantheus?

Summary

How does Mineralys Therapeutics compare to Amneal Pharmaceuticals?

Summary

How does Mineralys Therapeutics compare to Liquidia?

Summary

How does Mineralys Therapeutics compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. BLTE, LNTH, AMRX, LQDA, and DFTX

How does Mineralys Therapeutics compare to Belite Bio?

Is BLTE or MLYS more profitable?

Which has more volatility and risk, BLTE or MLYS?

Do analysts prefer BLTE or MLYS?

Do insiders and institutionals hold more shares of BLTE or MLYS?

Which has stronger valuation & earnings, BLTE or MLYS?

Does the media favor BLTE or MLYS?

Summary

How does Mineralys Therapeutics compare to Lantheus?

Do analysts prefer MLYS or LNTH?

Which has more volatility & risk, MLYS or LNTH?

Is MLYS or LNTH more profitable?

Do insiders & institutionals hold more shares of MLYS or LNTH?

Does the media prefer MLYS or LNTH?

Which has stronger valuation & earnings, MLYS or LNTH?

Summary

How does Mineralys Therapeutics compare to Amneal Pharmaceuticals?

Which has more volatility and risk, MLYS or AMRX?

Do analysts rate MLYS or AMRX?

Is MLYS or AMRX more profitable?

Which has preferable earnings and valuation, MLYS or AMRX?

Does the media refer more to MLYS or AMRX?

Do institutionals and insiders believe in MLYS or AMRX?

Summary

How does Mineralys Therapeutics compare to Liquidia?

Which has stronger earnings & valuation, LQDA or MLYS?

Which has more volatility and risk, LQDA or MLYS?

Do analysts prefer LQDA or MLYS?

Is LQDA or MLYS more profitable?

Does the media refer more to LQDA or MLYS?

Do institutionals & insiders hold more shares of LQDA or MLYS?

Summary

How does Mineralys Therapeutics compare to Definium Therapeutics?

Which has more volatility & risk, DFTX or MLYS?

Do analysts prefer DFTX or MLYS?

Which has preferable valuation & earnings, DFTX or MLYS?

Is DFTX or MLYS more profitable?

Do institutionals and insiders hold more shares of DFTX or MLYS?

Does the media favor DFTX or MLYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools